ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

MethddPCR-ctDNA is an independent prognostic biomarker for OS in advanced/metastatic EC. MethddPCR-ctDNA may identify patients unlikely to benefit from PARP inhibition, guide therapeutic decisions, and should be further evaluated as a new stratification parameter in future endometrial carcinoma trials.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2026-01-15
DOI
https://doi.org/10.1158/1078-0432.ccr-25-2959
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

V. Taly, I. Ray-Coquard, Cyril Foa, Corina Cornila et al.
Clinical Cancer Research
Cancer Genomics and Diagnostics
article

ctDNA for Prognostication and Monitoring in Patients with Metastatic Endometrial Carcinoma Treated with Olaparib: Validation in the GINECO-UTOLA Trial

V. Taly, I. Ray-Coquard, Cyril Foa, Corina Cornila, M. Rodrigues, P. Fournel, Sophie Abadie‐Lacourtoisie, Guillaume Beinse, Patrick Bouchaert, V. D'Hondt, Guillaume Meynard, Emilie Kaczmarek, Alexandra Leary, F. Selle, Jérôme Alexandre, Benoît You, Pierre-Emmanuel Brachet, Florence Joly, Isabelle Cojean Zelek, Marie Ange Mouret-Reynier, Anne-Claire Hardy-Bessard, Sophie Roche, Coriolan Lebreton, Leïla Bengrine-Lefevre, Rémy Largillier, Aurelia Baures, Pierre Laurent-Puig, Delphine Duliege
article en

Abstract

MethddPCR-ctDNA is an independent prognostic biomarker for OS in advanced/metastatic EC. MethddPCR-ctDNA may identify patients unlikely to benefit from PARP inhibition, guide therapeutic decisions, and should be further evaluated as a new stratification parameter in future endometrial carcinoma trials.

Clinical Cancer Research
Université Claude Bernard Lyon 1 (FR), Université d'Orléans (FR), Université Paris Cité (FR), Institut Gustave Roussy (FR), Centre Hospitalier Universitaire de Besançon (FR), Centre de Recherche des Cordeliers (FR), Audionamix (France) (FR), Centre Georges François Leclerc (FR), Université Paul-Valéry Montpellier (FR), Hospices Civils de Lyon (FR), Centre François Baclesse (LU), Hôpital Européen Georges-Pompidou (FR), Centre Hospitalier Universitaire de Nîmes (FR), Centre Léon Bérard (FR), Hôpital Européen (FR), Centre Hospitalier Universitaire de Poitiers (FR), Hôpital Lyon Sud (FR), Groupe Hospitalier Diaconesses Croix Saint-Simon (FR), Institut Génétique Nantes Atlantique (FR), Hôpital Saint Joseph (FR), Centre François Baclesse (FR), Centre Jean Bernard (FR), Centre Jean Perrin (FR), Institut Claudius Regaud (FR), Centre Oscar Lambret (FR), Centre Azuréen de Cancérologie (FR), Institut Bergonié (FR), Arcagy Gineco (FR), Centre hospitalier universitaire d'Orléans (FR), Centre Hospitalier René-Dubos (FR), Eau de Paris (France) (FR), Centro Universitário Carioca (BR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Hôpital Intercommunal de Créteil (FR), Université d'Angers (FR), Institut Curie (FR), HCL Technologies (India) (IN)
No poverty
Openalex Percentile: Top 87%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.